Olink publishes 2023 annual report
25. März 2024 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at...
Olink reports fourth quarter and full year 2023 financial results
25. März 2024 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. ...
Notice to attend the Annual General Meeting of Olink Holding AB (publ)
15. März 2024 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General...
Olink announces change of date for Annual General Meeting
08. März 2024 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden...
Olink reports third quarter 2023 financial results
15. November 2023 07:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023. ...
Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics
05. November 2023 20:00 ET
|
Olink Proteomics AB
Novogene AMEA to begin offering Olink Explore HT high-throughput proteomics services to unravel the connections between genes, proteins, and diseases.
Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
05. Oktober 2023 16:25 ET
|
Olink Proteomics AB
Three landmark studies published in Nature demonstrate the power of Olink technology for understanding human biology.
Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
19. September 2023 03:00 ET
|
Olink Proteomics AB
Uppsala, Sweden, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research. ...
Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
12. September 2023 11:00 ET
|
Olink Proteomics AB
Uppsala, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs UPPSALA, Sweden, 12th...
Olink to participate in September investor events
29. August 2023 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: ...